Ception Therapeutics - Top 20 VC deals of 2007

Company: Ception Therapeutics
Based: Malvern, PA
Amount: $77.7M
Round: Third
Investors: Aperture Venture Partners, Essex Woodlands Health Ventures, Greenlight Capital, Individuals, Investor Growth Capital, Lumira Capital Corporation, New Science Ventures, Undisclosed Investor

Scoop: Ception's pipeline includes a late-stage biologic agent (Anti-IL5 MAb) in clinical development for eosinophilic esophagitis and other inflammatory conditions. The company is also working on an oral Anti-TNF drug, an anti-infective program and a novel anti-thrombotic program.

More News:
Ception adds $14.7M to big third round. Report
Ception Therapeutics pockets $63M in third round. Report

Ception Therapeutics - Top 20 VC deals of 2007
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.